Literature DB >> 30975908

Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report.

Katrine F Iversen1, Paw C Holdgaard2, Birgitte Preiss3, Charlotte G Nyvold4, Torben Plesner5.   

Abstract

Entities:  

Year:  2019        PMID： 30975908      PMCID： PMC6717591          DOI： 10.3324/haematol.2018.214635

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authors:  Joan Montero; Jason Stephansky; Tianyu Cai; Gabriel K Griffin; Lucia Cabal-Hierro; Katsuhiro Togami; Leah J Hogdal; Ilene Galinsky; Elizabeth A Morgan; Jon C Aster; Matthew S Davids; Nicole R LeBoeuf; Richard M Stone; Marina Konopleva; Naveen Pemmaraju; Anthony Letai; Andrew A Lane
Journal:  Cancer Discov       Date:  2016-12-16       Impact factor: 39.397

3.  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.

Authors:  J Menezes; F Acquadro; M Wiseman; G Gómez-López; R N Salgado; J G Talavera-Casañas; I Buño; J V Cervera; S Montes-Moreno; J M Hernández-Rivas; R Ayala; M J Calasanz; M J Larrayoz; L F Brichs; M Gonzalez-Vicent; D G Pisano; M A Piris; S Álvarez; J C Cigudosa
Journal:  Leukemia       Date:  2013-09-27       Impact factor: 11.528

4.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Alessandro Pulsoni; Simona Fisogni; Paola Carluccio; Francesco Mannelli; Monia Lunghi; Gianmatteo Pica; Francesco Onida; Chiara Cattaneo; Pier Paolo Piccaluga; Eros Di Bona; Elisabetta Todisco; Pellegrino Musto; Antonio Spadea; Alfonso D'Arco; Stefano Pileri; Giuseppe Leone; Sergio Amadori; Fabio Facchetti
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.

Authors:  Uday Deotare; Karen W L Yee; Lisa W Le; Anna Porwit; Anne Tierens; Rumina Musani; David Barth; Emina Torlakovic; Aaron Schimmer; Andre C Schuh; Matthew Seftel; Mark D Minden; Vikas Gupta; Elizabeth Hyjek
Journal:  Am J Hematol       Date:  2016-01-11       Impact factor: 10.047

6.  Novel markers of normal and neoplastic human plasmacytoid dendritic cells.

Authors:  Teresa Marafioti; Jennifer C Paterson; Erica Ballabio; Kaaren K Reichard; Sara Tedoldi; Kevin Hollowood; Michael Dictor; Martin-Leo Hansmann; Stefano A Pileri; Martin J Dyer; Silvano Sozzani; Ivan Dikic; Andrey S Shaw; Tony Petrella; Harald Stein; Peter G Isaacson; Fabio Facchetti; David Y Mason
Journal:  Blood       Date:  2008-01-24       Impact factor: 22.113

Review 7.  Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.

Authors:  Livio Pagano; Caterina G Valentini; Sara Grammatico; Alessandro Pulsoni
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

8.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Authors:  Jakub Krejcik; Tineke Casneuf; Inger S Nijhof; Bie Verbist; Jaime Bald; Torben Plesner; Khaja Syed; Kevin Liu; Niels W C J van de Donk; Brendan M Weiss; Tahamtan Ahmadi; Henk M Lokhorst; Tuna Mutis; A Kate Sasser
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

9.  Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.

Authors:  Laure Philippe; Adam Ceroi; Elodie Bôle-Richard; Alizée Jenvrin; Sabeha Biichle; Sophie Perrin; Samuel Limat; Francis Bonnefoy; Eric Deconinck; Philippe Saas; Francine Garnache-Ottou; Fanny Angelot-Delettre
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

10.  Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report.

Authors:  Marta Garcia-Recio; Jordi Martinez-Serra; Leyre Bento; Rafael Ramos; Jordi Gines; Jaime Daumal; Antonia Sampol; Antonio Gutierrez
Journal:  Onco Targets Ther       Date:  2016-09-07       Impact factor: 4.147
View more
  5 in total

Review 1.  Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Authors:  Minas P Economides; David Rizzieri; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Elodie Bôle-Richard; Naveen Pemmaraju; Blandine Caël; Etienne Daguindau; Andrew A Lane
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

3.  Case Report of Anti-CD123 Chimeric Antigen Receptor T-Cell Therapy Followed by Radiotherapy for a Recurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yi-Li Jiang; Qing Li; Ting Yuan; Yan-Yu Jiang; Qi Deng
Journal:  Onco Targets Ther       Date:  2020-04-22       Impact factor: 4.147

Review 4.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 5.  Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Yumeng Zhang; Lubomir Sokol
Journal:  Cancer Manag Res       Date:  2022-06-28       Impact factor: 3.602
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.